company background image
CTXR

Citius PharmaceuticalsNasdaqCM:CTXR Stock Report

Market Cap

US$305.1m

7D

0.5%

1Y

109.0%

Updated

25 Sep, 2021

Data

Company Financials +
CTXR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CTXR Overview

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.

Price History & Performance

Summary of all time highs, changes and price drops for Citius Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.09
52 Week HighUS$0.87
52 Week LowUS$4.56
Beta1.53
1 Month Change0.48%
3 Month Change-45.29%
1 Year Change109.00%
3 Year Change22.22%
5 Year Change-77.88%
Change since IPO-86.07%

Recent News & Updates

Shareholder Returns

CTXRUS PharmaceuticalsUS Market
7D0.5%0.5%0.1%
1Y109.0%14.3%35.3%

Return vs Industry: CTXR exceeded the US Pharmaceuticals industry which returned 14.3% over the past year.

Return vs Market: CTXR exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Beta1.53
Industry Beta0.64
Market Beta1

Stable Share Price: CTXR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CTXR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200710Myron Holubiakhttps://www.citiuspharma.com

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Fundamentals Summary

How do Citius Pharmaceuticals's earnings and revenue compare to its market cap?
CTXR fundamental statistics
Market CapUS$305.10m
Earnings (TTM)-US$23.66m
Revenue (TTM)n/a

0x

P/S Ratio

-12.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTXR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$23.66m
Earnings-US$23.66m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.1%

How did CTXR perform over the long term?

See historical performance and comparison

Valuation

Is Citius Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

2.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CTXR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CTXR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTXR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTXR is good value based on its PB Ratio (2.2x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Citius Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

256.9%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CTXR's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if CTXR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CTXR's revenue (256.9% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CTXR's revenue (256.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTXR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Citius Pharmaceuticals performed over the past 5 years?

-19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTXR is currently unprofitable.

Growing Profit Margin: CTXR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.

Accelerating Growth: Unable to compare CTXR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTXR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: CTXR has a negative Return on Equity (-16.18%), as it is currently unprofitable.


Financial Health

How is Citius Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CTXR's short term assets ($116.9M) exceed its short term liabilities ($3.6M).

Long Term Liabilities: CTXR's short term assets ($116.9M) exceed its long term liabilities ($5.7M).


Debt to Equity History and Analysis

Debt Level: CTXR's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: CTXR's debt to equity ratio has reduced from 1% to 0.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTXR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CTXR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30% each year


Dividend

What is Citius Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTXR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTXR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTXR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTXR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTXR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.7yrs

Average management tenure


CEO

Myron Holubiak (74 yo)

5.5yrs

Tenure

US$875,035

Compensation

Mr. Myron Z. Holubiak has been the Chief Executive Officer and President of Citius Pharmaceuticals, Inc. since March 30, 2016 and has been its Director since October 1, 2015. Mr. Holubiak served as an Advi...


CEO Compensation Analysis

Compensation vs Market: Myron's total compensation ($USD875.04K) is below average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Myron's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CTXR's management team is considered experienced (4.7 years average tenure).


Board Members

Experienced Board: CTXR's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 163.1%.


Top Shareholders

Company Information

Citius Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Citius Pharmaceuticals, Inc.
  • Ticker: CTXR
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$305.097m
  • Shares outstanding: 145.98m
  • Website: https://www.citiuspharma.com

Number of Employees


Location

  • Citius Pharmaceuticals, Inc.
  • 11 Commerce Drive
  • First Floor
  • Cranford
  • New Jersey
  • 7016
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 22:06
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.